BRPI0511906A - isolamento de proteìnas do plasma ou soro - Google Patents

isolamento de proteìnas do plasma ou soro

Info

Publication number
BRPI0511906A
BRPI0511906A BRPI0511906-5A BRPI0511906A BRPI0511906A BR PI0511906 A BRPI0511906 A BR PI0511906A BR PI0511906 A BRPI0511906 A BR PI0511906A BR PI0511906 A BRPI0511906 A BR PI0511906A
Authority
BR
Brazil
Prior art keywords
plasma
protein solution
protein
isolation
serum proteins
Prior art date
Application number
BRPI0511906-5A
Other languages
English (en)
Inventor
Allan Otto Fog Lihme
Original Assignee
Upfront Chromatography As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upfront Chromatography As filed Critical Upfront Chromatography As
Publication of BRPI0511906A publication Critical patent/BRPI0511906A/pt
Publication of BRPI0511906B1 publication Critical patent/BRPI0511906B1/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/206—Packing or coating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ISOLAMENTO DE PROTEìNAS DO PLASMA OU SORO. A presente invenção refere-se a um processo para o isolamento de uma ou mais proteína(s) a partir de uma solução de proteína. O processo compreendendo as etapas de: a) provisão de uma solução de proteína compreendendo uma ou mais proteína(s) específicas e tendo um pH e uma resistência ou condutividade iónica pré-ajustada, b) aplicação da solução de proteína a uma coluna de leito revestido ou leito expandido compreendendo um absorvente e c) obtenção de uma ou mais proteínas a partir da coluna; onde a solução de proteína foi suplementada com um álcool.
BRPI0511906-5A 2004-06-07 2005-06-07 Processo para o isolamento em grande escala de uma ou mais proteína(s) a partir de uma solução de proteína BRPI0511906B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400891 2004-06-07
DKPA200400891 2004-06-07
DKPA200401062 2004-07-05
DKPA200401062 2004-07-05
PCT/DK2005/000378 WO2005121163A2 (en) 2004-06-07 2005-06-07 Isolation of plasma or serum proteins

Publications (2)

Publication Number Publication Date
BRPI0511906A true BRPI0511906A (pt) 2008-01-15
BRPI0511906B1 BRPI0511906B1 (pt) 2021-11-30

Family

ID=34969001

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511906-5A BRPI0511906B1 (pt) 2004-06-07 2005-06-07 Processo para o isolamento em grande escala de uma ou mais proteína(s) a partir de uma solução de proteína

Country Status (10)

Country Link
US (3) US9624260B2 (pt)
EP (3) EP2277912B1 (pt)
CN (2) CN1972961B (pt)
AU (2) AU2005252296B2 (pt)
BR (1) BRPI0511906B1 (pt)
DK (1) DK1765866T3 (pt)
ES (2) ES2454566T3 (pt)
PL (1) PL1765866T3 (pt)
PT (1) PT1765866E (pt)
WO (1) WO2005121163A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1664123E (pt) * 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
CA2544816A1 (en) 2003-11-08 2005-05-26 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
RU2007100351A (ru) * 2004-06-07 2008-07-20 ЭйВиТи ПЛАЗМА ЛИМИТЕД (AU) Способ выделения белка
EP2277912B1 (en) 2004-06-07 2016-09-28 Therapure Biopharma Inc. Isolation of plasma proteins
WO2007063129A2 (en) * 2005-12-02 2007-06-07 Novozymes A/S Insolation of peptides , polypeptides and proteins
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20120177610A1 (en) 2007-09-19 2012-07-12 Kieu Hoang Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
US20110065900A1 (en) * 2008-05-30 2011-03-17 Ge Healthcare Bio-Science Ab Separation method utilizing polyallylamine ligands
KR20160104740A (ko) * 2008-06-24 2016-09-05 옥타파마 아게 응고 인자 ｖｉｉｉ을 정제하는 방법
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
MX2012011066A (es) 2010-03-30 2012-10-10 Octapharma Ag Proceso para purificar proteinas dependientes de vitamina k tal como el factor ix de coagulacion.
CN102858797B (zh) 2010-03-30 2016-05-11 奥克塔法马股份有限公司 纯化生长因子蛋白的方法
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
US8802448B2 (en) 2011-07-27 2014-08-12 Pall Corporation Mixed mode ligands
TW201335181A (zh) * 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
GB201206530D0 (en) * 2012-04-13 2012-05-30 Vivacta Ltd An assay label
US20140031527A1 (en) * 2012-07-27 2014-01-30 Csl Limited Method for polishing albumin
CA2885604A1 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of ischemia using inter-alpha inhibitor proteins
CN102977180B (zh) * 2012-11-06 2016-03-16 中国科学院过程工程研究所 一种综合利用Cohn组分IV的方法
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
CN103130868B (zh) * 2013-03-12 2014-09-17 合肥天麦生物科技发展有限公司 一种蛋白质或多肽的纯化方法
CN104236983A (zh) * 2013-06-14 2014-12-24 中国科学院大连化学物理研究所 溶液样品中含长烷基链的离子液体的去除方法
US9663553B2 (en) * 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
WO2017058877A1 (en) * 2015-09-28 2017-04-06 Kieu Hoang A method for separating proteins from animal or human plasma, or plants, using a ph gradient method
CN106085992A (zh) * 2016-06-16 2016-11-09 武汉中原瑞德生物制品有限责任公司 一种提高人凝血酶原复合物中fⅶ收率的方法
US11866743B1 (en) 2017-05-31 2024-01-09 Teledyne Flir Detection, Inc. Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules
WO2020160505A1 (en) * 2019-02-01 2020-08-06 Ohio State Innovation Foundation Methods of protein purification
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
CN110215739A (zh) * 2019-07-15 2019-09-10 大连医科大学 一种离子型亲水前处理硅胶材料的制备方法
CN111603802A (zh) * 2020-05-10 2020-09-01 上海灿实工程设备有限公司 一种用于血液制品的吸附罐
CN112409476B (zh) * 2020-08-13 2022-03-29 中元汇吉生物技术股份有限公司 四种血液来源蛋白的纯化方法
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
CN112827217A (zh) * 2020-12-29 2021-05-25 苏州良辰生物医药科技有限公司 一种层析柱清洗液及其应用
CA3228624A1 (en) * 2021-09-28 2023-04-06 LIHME PROTEIN SOLUTIONS ApS Improved protein sorption and filtration apparatus

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
US2469193A (en) 1942-02-09 1949-05-03 Research Corp Protein fractionation
US4156681A (en) 1974-03-28 1979-05-29 Plasmesco Ag Process for isolating albumin from blood
JPS57168157A (en) * 1981-02-12 1982-10-16 Asahi Chem Ind Co Ltd High performance liquid chromatography column and analysis method using the same
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
DK165090D0 (da) 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
DK52791D0 (da) 1991-03-22 1991-03-22 Kem En Tec As Adsorptionsmatricer
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
US5502022A (en) 1994-05-16 1996-03-26 Biosepra, Inc. Chromatography adsorbents utilizing mercapto heterocyclic ligands
DE69532492T2 (de) 1994-08-31 2004-12-02 Mitsubishi Pharma Corp. Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
US5837826A (en) 1995-02-27 1998-11-17 Regents Of The University Of Minnesota Protein adsorption by very dense porous zirconium oxide particles in expanded beds
SE9503926D0 (sv) * 1995-11-07 1995-11-07 Pharmacia Biotech Ab Adsorptionsförfarande och separationsmedium
TW491855B (en) * 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
AU729039C (en) * 1996-08-30 2001-08-02 Upfront Chromatography A/S Isolation of immunoglobulins
IL137649A (en) * 1998-02-18 2004-08-31 Genentech Inc Method of adsorption chromatography
US20020104801A1 (en) * 1998-04-06 2002-08-08 Nicolas Voute Small dense microporous solid support materials, their preparation,and use for purification of large macromolecules and bioparticles
DE19823814A1 (de) * 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
WO1999065586A2 (en) 1998-06-18 1999-12-23 Upfront Chromatography A/S Expanded bed adsorption system
AU767183B2 (en) 1998-10-31 2003-11-06 Ge Healthcare Bio-Sciences Ab A new system and its units
WO2000057982A1 (en) 1999-03-26 2000-10-05 Upfront Chromatography A/S Fluidised bed purification of bio-macromolecules such as plasmid dna, chromosomal dna, rna, viral dna, bacteria and viruses
AU5823801A (en) 2000-05-12 2001-11-20 Upfront Chromatography As A bed adsorption system
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
WO2002053251A1 (en) 2000-12-29 2002-07-11 Upfront Chromatography A/S Extracorporeal capturing of specific bio-macromolecular entities from extracellular body fluids
ATE290323T1 (de) * 2001-06-01 2005-03-15 Upfront Chromatography As Fraktionierung von proteinhaltigen mischungen
CN1207064C (zh) * 2002-03-29 2005-06-22 华兰生物工程股份有限公司 一种冻干人纤维蛋白胶的生产工艺
AU2003242509A1 (en) 2002-07-11 2004-02-02 Upfront Chromatography A/S An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis
EP1605772B1 (en) * 2003-03-21 2007-06-27 Upfront Chromatography A/S Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems
EP2277912B1 (en) 2004-06-07 2016-09-28 Therapure Biopharma Inc. Isolation of plasma proteins
EP2522354B1 (en) * 2011-05-12 2017-08-23 CSL Behring GmbH Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins

Also Published As

Publication number Publication date
US20170282095A1 (en) 2017-10-05
EP2277912A3 (en) 2011-05-04
ES2606078T3 (es) 2017-03-17
PL1765866T3 (pl) 2014-06-30
EP3127916A1 (en) 2017-02-08
WO2005121163A2 (en) 2005-12-22
US9624260B2 (en) 2017-04-18
EP2277912B1 (en) 2016-09-28
CN102924565A (zh) 2013-02-13
EP1765866B1 (en) 2014-01-08
CN1972961B (zh) 2012-12-26
DK1765866T3 (en) 2014-03-24
WO2005121163A3 (en) 2006-03-23
ES2454566T3 (es) 2014-04-10
AU2009238344B2 (en) 2012-02-16
US20070299251A1 (en) 2007-12-27
EP2277912A2 (en) 2011-01-26
PT1765866E (pt) 2014-04-14
US20160009757A1 (en) 2016-01-14
AU2009238344A1 (en) 2009-12-10
EP1765866A2 (en) 2007-03-28
US9428545B2 (en) 2016-08-30
BRPI0511906B1 (pt) 2021-11-30
CN1972961A (zh) 2007-05-30
AU2005252296A1 (en) 2005-12-22
AU2005252296B2 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
BRPI0511906A (pt) isolamento de proteìnas do plasma ou soro
AU2016222301A1 (en) Isolation and purification of antibodies using Protein A affinity chromatography
BR112012009289B8 (pt) método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BRPI0920572A8 (pt) Inativação viral durante a purificação dos anticorpos
EP2428225A3 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
BRPI0620125A8 (pt) método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
ATE538199T1 (de) Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins
BRPI0607751A8 (pt) organismo hospedeiro, sistema de cultura de célula, método para melhorar a produtividade da expressão de proteína dependente da vitamina k recombinante ou de um derivado desta funcionalmente ativo em um organismo hospedeiro, e, proteína dependente da vitamina k recombinante
EP1969127B8 (en) Method of producing biologically active vitamin k dependent proteins by recombinant methods
BRPI0721238B8 (pt) método de purificação da apolipoproteina a-1
WO2009153751A3 (en) A method for enzymatic cross-linking of a protein
EA201491564A1 (ru) Осаждение фракции i-iv-1 иммуноглобулинов из плазмы
BRPI0509263A (pt) processo para purificar mesotriona
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
WO2007063129A3 (en) Insolation of peptides , polypeptides and proteins
BRPI0608367A2 (pt) composição para redução de exsudação de proteìnas de soro
WO2008054595A3 (en) Drug controlled molecular tags
BRPI0511893A (pt) processo para isolamento de proteìna
BR0318575A (pt) método para preparar dispositivos médicos para eluição de fármacos e dispositivo obtido deles
BRPI0518894A2 (pt) uso da cinase regulada por soro/glicocorticàide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: THERAPURE BIOPHARMA INC (CA)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: THERAPURE BIOPHARMA INC (CA)

B25A Requested transfer of rights approved

Owner name: THERAPURE BIOPHARMA INC (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: EVOLVE BIOLOGICS INC. (CA)